Nicholas Latimer - Publications

Journal articles

Conference proceedings papers

  • Thomas SA, Drummond A, Lincoln NB, Palmer R, dasnair R, Latimer N, Hackney G, Hatton R, Walters S, Mandefield L, Cooper C, Chater T, Callaghan P, England TJ, Coates L, Sutherland K & Eshtan S (2017) Behavioural activation therapy for depression after stroke (BEADS): a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression. INTERNATIONAL JOURNAL OF STROKE, Vol. 12 (pp 15-15)
  • Latimer N & Abrams KR (2017) TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 20(5) (pp A314-A314) View this article in WRRO
  • Watkins CL, Latimer N, Wang J & Wright EJ (2016) GUIDANCE ON SELECTING APPROPRIATE METHODS WHEN CONSIDERING ADJUSTING OVERALL SURVIVAL FOR TREATMENT SWITCH IN ONCOLOGY STUDIES. VALUE IN HEALTH, Vol. 19(7) (pp A398-A398)
  • Bell H, Latimer N, Amonkar M & Swann S (2015) Adjusting For Treatment Switching in Rcts – Identifying, Analysing and Justifying Appropriate Methods: a Case Study in Metastatic Melanoma. Value in Health, Vol. 18(7) (pp A338-A338)
  • Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Bartlett-Pandite AN & Motzer R (2015) Crossover in oncology clinical trials. JOURNAL OF CLINICAL ONCOLOGY, Vol. 33(15)
  • Bell H, Latimer N, Amonkar M & Casey M (2014) Adjusting for Treatment Crossover in A Trametinib Metastatic Melanoma Rct: Identifying the Appropriate Method. Value in Health, Vol. 17(7) (pp A577-A577)
  • Latimer N, Amonkar M, Stapelkamp C & Sun P (2014) Abstract CT330: Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Cancer Research, Vol. 74(19 Supplement) (pp CT330-CT330)
  • Boucher R, Abrams KR, Crowther MJ, Lambert PC, Wailoo AJ & Latimer NR (2013) ADJUSTING FOR TREATMENT SWITCHING IN CLINICAL TRIALS WHEN ONLY SUMMARY DATA ARE AVAILABLE - AN EVALUATION OF POTENTIAL METHODS. VALUE IN HEALTH, Vol. 16(7) (pp A610-A611)
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2013) A GUIDE TO ADJUSTING SURVIVAL TIME ESTIMATES TO ACCOUNT FOR TREATMENT SWITCHING IN RANDOMISED CONTROLLED TRIALS. VALUE IN HEALTH, Vol. 16(7) (pp A325-A325)
  • Paracha N, Davies A, Latimer N, Parker C, Mealing S, Scott D, Padhiar A, Schulpher M & Wang Q (2013) The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Abrams KR, Latimer N, Amonkar M, Stapelkamp C, Casey M & Grp T (2013) Adjusting for treatment crossover in the METRIC metastatic melanoma (MM) trial for trametinib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Latimer N, Abrams KR, Amonkar M, Stapelkamp C & Swann RS (2013) Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Latimer N, Lambert P, Crowther M, Abrams KR, Wailoo AJ & Morden JP (2012) METHODS FOR ESTIMATING SURVIVAL BENEFITS IN THE PRESENCE OF TREATMENT CROSSOVER: A SIMULATION STUDY. VALUE IN HEALTH, Vol. 15(7) (pp A462-A462)
  • Latimer N (2011) METHODS FOR EXTRAPOLATING SURVIVAL DATA USED IN NICE TECHNOLOGY APPRAISALS: INCONSISTENCIES AND LIMITATIONS. VALUE IN HEALTH, Vol. 14(7) (pp A242-A242)
  • Rowen D, Mulhern B, Brazier J, Jacoby A, Marson T, Latimer N, Snape D, Baker G & Hughes D (2010) Using the Liverpool Quality of Life battery to develop a health state classification system for Epilepsy. QUALITY OF LIFE RESEARCH, Vol. 19 (pp 57-57)
  • Gyldmark M, Gatzemeier U, Nicolson M, Latimer N & Walzer S (2008) EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM. VALUE HEALTH, Vol. 11(6) (pp A357-A357)
  • Ducournau P, Latimer N, Sabate E & Walzer S (2008) EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE. VALUE HEALTH, Vol. 11(6) (pp A471-A472)
  • Somerville M, Scott D, Hancock M, Geary U & Latimer N (2008) The impact of rituximab on resource use in a UKNHS rheumatology day care service. RHEUMATOLOGY, Vol. 47 (pp II119-II120)
  • Latimer N & Lewis G (2008) What are the costs of treating severe active rheumatoid arthritis with TNF inhibitors, rituximab and abatacept?. RHEUMATOLOGY, Vol. 47 (pp II122-II123)
  • Latimer N & Lewis G (2008) The cost of adults with severe active rheumatoid arthritis who do not respond to treatment following treatment with one TNF inhibitor. RHEUMATOLOGY, Vol. 47 (pp II123-II124)
  • Latimer NR & Lewis GJ (2005) A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK. VALUE HEALTH, Vol. 8(6) (pp A58-A58)

Reports

  • Latimer NR, White IR, Abrams KR & Sieburt U (2017) Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?

Scholarly editions

  • Mulhern B, Rowen D, Brazier J, Jacoby A, Marson T, Snape D, Hughes D, Latimer N & Baker GA (2010) Developing a health state classification system from NEWQOL for epilepsy using classical psychometric techniques and Rasch analysis: a technical report.